Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5 million – including $175 million upfront and an equity investment of $50 million – to find ...

Today's best phones can command prices upwards of $999. Fortunately, there are plenty of cell phone deals for new and existing customers alike. Whether you're looking for unlocked phones ...